Les publications

Page en cours de mise à jour... Retrouvez ici les publications des équipes de recherche du CGO

384 publications
Année de publication :
Réseaux :

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1…

Background: Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological markers, based on circulating immune cell subsets associated with therapeutic efficacy are yet to be validated.

  • Ref: J Immunother Cancer. 2020 Nov;8(2):e001631.
  • Année de publication : 2020
  • Auteurs : Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, Adotevi O, Laheurte C, Aubin F, Nardin C, Rulli S, Gottardo R, Ramchurren N, Cheever M, Fling SP, Church CD, Nghiem P, Dreno B, Riddell SR, Labarriere N.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Macrophages: Checking Toxicity of Fungal Metabolites in the Colon.

It is well known that the intestine absorbs nutrients, electrolytes, and water. Chikina et al. recently demonstrated that it is also able to sense, recognize, and block the absorption of toxins through a very sophisticated interactive cellular cooperation between novel subpopulations of macrophages and epithelial cells.

  • Ref: Trends Endocrinol Metab. 2020 Dec 17:S1043-2760(20)30248-4.
  • Année de publication : 2020
  • Auteurs : Blatzer M, Papon N, Delneste Y, Latgé JP.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with…

Purpose: Report results of the phase Ib dose-escalation/expansion study of triplet therapy with cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor (ribociclib), mTOR inhibitor (everolimus), and endocrine therapy (exemestane).

  • Ref: Clin Cancer Res. 2020 Dec 15;26(24):6417-6428.
  • Année de publication : 2020
  • Auteurs : Bardia A, Modi S, Oliveira M, Cortes J, Campone M, Ma B, Dirix L, Weise A, Hewes B, Diaz-Padilla I, Han Y, Deshpande P, Samant TS, Lorenc KR, He W, Su F, Chavez-MacGregor M.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast…

In most cases, metastatic breast cancer remains an incurable disease. A PIK3CA mutation is detected in 30-40% of all hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancers. PIK3CA activating mutations have been linked to endocrine resistance.

  • Ref: Expert Opin Drug Metab Toxicol. 2020 Dec 8:1-14.
  • Année de publication : 2020
  • Auteurs : Bertho M, Patsouris A, Augereau P, Robert M, Frenel JS, Blonz C, Campone M.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast…

Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the first few years.

  • Ref: J Clin Oncol. 2020 Dec 1;38(34):3987-3998.
  • Année de publication : 2020
  • Auteurs : Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; monarchE Committee Members and Investigators.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Amélioration de la classification du risque intermédiaire du cancer de la prostate avec les données IRM…

Le cancer de la prostate de risque intermédiaire est désormais classé en pronostic favorable et défavorable, en fonction du score ISUP, du PSA, du toucher rectal et du pourcentage de biopsies positives. Notre objectif était d’évaluer l’apport de l’imagerie et des biopsies ciblées pour améliorer cette classification à partir de l’analyse du stade histopathologique après prostatectomie totale.

  • Ref: Prog Urol. 2020 Nov;30(13):776.
  • Année de publication : 2020
  • Auteurs : Thenault R, Gasmi A, Kaulanjan K, Goujon A, Courboin E, Manunta A, Verhoest G, Vincendeau S, Bensalah K, Khene Z, Peyronnet B, Mathieu R.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

A cohort study of banana plantation workers in the French West Indies: first mortality analysis (2000-2015).

Chlordecone, an organochlorine insecticide, was widely used in the French West Indies banana plantations. We set up a cohort of banana plantation workers who worked between 1973 and 1993, the period of authorized use of chlordecone. Vital status and causes of death were collected from French national registries.

  • Ref: Environ Sci Pollut Res Int. 2020 Nov;27(33):41014-41022.
  • Année de publication : 2020
  • Auteurs : Luce D, Dugas J, Vaidie A, Michineau L, El-Yamani M, Multigner L.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases.

(1) Background: Stereotactic body radiotherapy (SBRT) for vertebral metastases (VM) allows the delivery of high radiation doses to tumors while sparing the spinal cord. We report a new approach to clinical target volume (CTV) delineation based on anti-carcinoembryonic antigen (CEA) positron emission tomography (pretargeted immuno-PET; “iPET”) in patients with metastatic breast cancer (BC) or medullary thyroid cancer (MTC).

  • Ref: Biomedicines. 2020 Nov 28;8(12):548.
  • Année de publication : 2020
  • Auteurs : Pichon B, Rousseau C, Blanc-Lapierre A, Delpon G, Ferrer L, Libois V, Le Turnier M, Lenoble C, Bodet-Milin C, Goldenberg DM, Kraeber-Bodere F, Supiot S.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

On the production of 52gMn by deuteron irradiation on natural chromium and its radionuclidic purity.

The positron emitter 52gMn is used for the Positron Emission Tomography – PET imaging.In this work we investigate the nuclear reactions for production of 52gMn and 54Mn induced by deuteron beams on natural chromium targets at energies up to Ed = 28 MeV using the stacked-foils activation technique.

  • Ref: Appl Radiat Isot. 2020 Dec;166:109329.
  • Année de publication : 2020
  • Auteurs : Bianchi F, Marchi C, Fuad G, Groppi F, Haddad F, Magagnin L, Manenti S.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.

Purpose: The aim of this study was to compare retrospectively 18F-DOPA PET/CT versus 68Ga-DOTANOC PET/CT in a group of patients affected by midgut NET.

Patients and methods: Patients with histologically proven grade 1 or grade 2 midgut NET were explored after injection of 150 MBq of 68Ga-DOTANOC and 210 MBq of 18F-DOPA. The PET/CTs were analyzed visually and semiquantitatively at the patient level, regional level (7 defined regions), and lesion level (maximum of 5 lesions/organ).

  • Ref: Clin Nucl Med. 2020 Dec 7.
  • Année de publication : 2020
  • Auteurs : Ansquer C, Touchefeu Y, Faivre-Chauvet A, Leux C, Le Bras M, Régenet N, Fleury V, Maucherat B, Senellart H, Guyetant S, Carlier T, Scotet-Cérato E, Rauscher A, Frampas E, Kraeber-Bodéré F.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication